|
Oscotec Inc. is a biotechnology company engaged in the discovery and development of synthetic new drugs, functional materials, and dental bone grafts. The company operates three main business segments: new drug development, functional materials and related products, and dental bone grafts. Its drug pipeline includes candidates for oncology, autoimmune diseases, and neurodegenerative disorders, with Lazertinib approved for non-small cell lung cancer and Cevidoplenib in development for immune thrombocytopenia. The company also markets bone graft materials such as BioCera-F, SynCera, and InduCera, as well as resorbable collagen membranes including CollaGuide and LysoGide. Oscotec serves domestic and international markets, with products sold through distributors and direct sales channels. The company collaborates with global pharmaceutical partners for the development and commercialization of its drug candidates. Founded in 1998, Oscotec was formerly known as OCT Inc. and has established subsidiaries including Ectodor Therapeutics Inc. and GENOSCO. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage oscotec.com |
| Sector Healthcare | IR page oscotec.com/investors | |
|
Tags
oncology, autoimmune diseases, neurodegenerative diseases, bone grafts, dental materials, synthetic drugs, targeted therapy, immunology, Lazertinib, Cevidoplenib, Adel-Y01, BioCera-F, SynCera, InduCera, CollaGuide, LysoGide, Ectodor Therapeutics Inc., GENOSCO, OCT USA Inc., Oscotec Central R&D Center
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 33.9% |
| ROI | 28.9% |
| ROIC | 28.7% |
| Profit margin | 52.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 46.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 99.839B | 34.008B | 4.951B | 5.062B | 3.903B | 43.471B | 4.369B | 18.703B | 3.908B | 3.554B | 18.336B | 17.11B | 21.859B |
| Net profit | 52.343B | 876.527M | -24.28B | -24.43B | -26.263B | -4.357B | -22.436B | 3.471B | -5.857B | -3.646B | 395.029M | -2.022B | -3.971B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 5.65B | 3.91B | 19.2B | 547M | 25.2B | 663M | 1.86B | 2.02B | 35.3B | 87.6B |
| ↳ YoY growth | +46.8% | -30.8% | +391.2% | -97.2% | +4,497.1% | -97.4% | +180.8% | +8.5% | +1,650.3% | +148.1% |
| ↳ 5y CAGR | +44.7% | -30.4% | +45.6% | -34.9% | -13.8% | -36.3% | +130.1% | +28.4% | ||
| Borrowings, current (KRW) | 8.47B | 11.1B | 9.16B | 4.8B | — | 6B | 9.29B | 6B | 13.6B | 15.5B |
| Borrowings, non-current (KRW) | 2.18B | 2.08B | 1.68B | 1.31B | 1.26B | 563M | 188M | — | — | — |
| Bonds payable (KRW) | 5.32B | 8.05B | 7.09B | 3.7B | — | — | — | — | 7.62B | 9.49B |
| Lease liabilities (KRW) | — | — | — | 223M | 86.9M | 313M | 227M | 164M | 198M | 133M |
| Cash and deposits (KRW) | 3.3B | 19.7B | 26.4B | 49.2B | 5.79B | 10.6B | 5.52B | 7.95B | 13.1B | 15.2B |
| Intangible assets (KRW) | 13.3B | 1.02B | 1.1B | 1.44B | 1.23B | 1.25B | 590M | 595M | 629M | 556M |
| Right-of-use assets (KRW) | — | — | — | — | 136M | 309M | 220M | 157M | 207M | 137M |
| Net debt (borrowings + leases - cash) (KRW) | -1.12B | -6.57B | -15.5B | -42.9B | -4.44B | -3.71B | 4.19B | -1.79B | 710M | 426M |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -3.37B | -3.69B | -5.08B | 27.5M | -17.9B | -8.76B | -26.4B | -22B | -26B | 8.3B |
| Change in receivables (cash effect) (KRW) | -6.49B | 2.28B | -14.3B | 15.7B | -27B | 25.1B | -1.2B | -148M | -31.5B | -54.5B |
| Change in inventories (cash effect) (KRW) | 194M | -56.9M | -117M | -14.2M | -80M | -107M | -64.5M | -433M | -68.7M | -45.8M |
| Change in payables (cash effect) (KRW) | 3.89B | 111M | 720M | -824M | 2.34B | -1.13B | 68.3M | 832M | 343M | 7.17B |
| Share buybacks (cash effect) (KRW) | -1.61B | — | — | — | — | — | — | — | — | — |
| Interest paid (cash effect) (KRW) | -289M | -244M | -164M | -176M | -103M | -104M | -303M | -410M | -270M | -237M |
| Income taxes paid (cash effect) (KRW) | -2.93M | -25.5M | -26.1M | -2.99B | 4.52M | -2.1B | 247M | 4.6B | -942M | 1.55B |
| Share-based compensation (KRW) | — | 23.9M | 130M | 134M | 310M | 57.1M | 109M | 434M | 1.27B | 546M |
| Operating cash flow before change in receivables (KRW) | 3.12B | -5.97B | 9.19B | -15.7B | 9.1B | -33.9B | -25.2B | -21.9B | 5.42B | 62.8B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | -3.95B | -6.27B | 5.11B | -24.8B | -3.18B | -26.8B | -26.9B | -28.5B | -2.24B | 55.7B |
| Comprehensive income to owners (KRW) | -3.29B | -5.52B | 4.15B | -22.4B | -5.18B | -27.1B | -23.8B | -24.3B | 477M | 53.7B |
| Provision for credit losses (KRW) | 140M | -53M | -53.1M | 651M | -108M | -2.33M | -6.25M | -427,261 | -130,217 | 132,173 |
| Credit cost ratio (credit losses / average receivables) (%) | 2.9% | 1.1% | 0.5% | 6.6% | 0.8% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% |
| Reported | Aug 24, 2018 | Aug 24, 2018 | Mar 29, 2019 | Mar 30, 2020 | Mar 9, 2021 | Mar 18, 2024 | Mar 18, 2024 | Mar 18, 2024 | Mar 19, 2025 | Mar 19, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding OCT Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.06% | 2,922 | $ 74.078K | Nov 16, 2026 |
| DEXC | 0.01% | 921 | $ 24.713K | Nov 12, 2026 |
| DFSE | 0.01% | 1,594 | $ 42.772K | Nov 12, 2026 |
| DFEM | 0.01% | 22,977 | $ 616.542K | Nov 12, 2026 |
| DFAE | 0.00% | 12,988 | $ 348.507K | Nov 12, 2026 |
| DFAX | 0.00% | 1,888 | $ 50.661K | Nov 12, 2026 |
| AVEM | 0.00% | 198 | $ 5,019.67 | Nov 16, 2026 |